Sage Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SAGE research report →
Companywww.sagerx.com
Sage Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults.
- CEO
- Barry E. Greene
- IPO
- 2014
- Employees
- 353
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $544.94M
- P/E
- -2.62
- P/S
- 9.31
- P/B
- 1.47
- EV/EBITDA
- -2.42
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 96.43%
- Op Margin
- -382.00%
- Net Margin
- -354.71%
- ROE
- -50.09%
- ROIC
- -58.82%
Growth & Income
- Revenue
- $41.24M · -52.30%
- Net Income
- $-400,666,000 · 26.01%
- EPS
- $-6.59 · 27.18%
- Op Income
- $-432,370,000
- FCF YoY
- 50.62%
Performance & Tape
- 52W High
- $9.36
- 52W Low
- $4.62
- 50D MA
- $8.29
- 200D MA
- $7.13
- Beta
- 0.30
- Avg Volume
- 2.48M
Get TickerSpark's AI analysis on SAGE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 25 | Quirk Michael C. | sell | 7,962 |
| Jul 31, 25 | Quirk Michael C. | sell | 36,000 |
| Jul 31, 25 | Quirk Michael C. | sell | 4,000 |
| Jul 31, 25 | Quirk Michael C. | sell | 24,999 |
| Jul 31, 25 | Federer Jessica | sell | 21,500 |
| Jul 31, 25 | Benecchi Christopher | sell | 12,500 |
| Jul 31, 25 | Benecchi Christopher | sell | 40,000 |
| Jul 31, 25 | Benecchi Christopher | sell | 28,053 |
| Jul 31, 25 | Benecchi Christopher | sell | 36,375 |
| Jul 31, 25 | COLA MICHAEL F | sell | 21,500 |
Our SAGE Coverage
We haven't published any research on SAGE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SAGE Report →